AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03117842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated text and voice messages
Description: Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
Study NCT01353014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary advice with genetic information
Description: This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
Study NCT01353014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General dietary recommendations
Description: This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
Study NCT04667442 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)
Description: COVID-19 Rapid Antigen Diagnostic Test
Study NCT02790502 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Food Photography Application©
Description: Group testing RFPM as method of recording plate waste
Study NCT02285816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1MA3
Description: MG1MA3: Boosting component of Oncolytic Vaccine
Study NCT02285816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdMA3
Description: AdMA3: Priming component of Oncolytic Vaccine
Study NCT01286870 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Becker 25 Expander/Breast Implant
Description: The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc.
Study NCT01286870 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Becker 50 Expander/Breast Implant
Description: The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc.
Study NCT01753323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAF156
Description: KAF156 was supplied as tablets for oral use.
Study NCT01657071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14659
Description: YH14659 capsule by oral
Study NCT01657071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel & aspirin
Description: clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
Study NCT02115542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (\<30% fat) breakfast.
Study NCT03558750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV
Study NCT03558750 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by IV
Study NCT03558750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given by mouth
Study NCT03950739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Inhalation Powder
Description: Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
Study NCT02978456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent
Description: In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro/Orsiro mission stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus \~10% of distal reference vessel diameter).
Study NCT02978456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro/Orsiro mission stent
Description: In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro/Orsiro mission stent size and length is selected by intravascular ultrasound measurements.
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Description: Oral tablet
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: Oral tablet
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral tablet
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Oral tablet
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match solifenacin succinate
Description: Oral tablet
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match solifenacin succinate
Description: Oral tablet
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match mirabegron
Description: Oral tablet
Study NCT04244552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Pegylated liposomal doxorubicin (PLD) is doxorubicin hydrochloride (HCl), an anthracycline topoisomerase inhibitor that can bind DNA and inhibit nucleic acid synthesis. PLD is doxorubicin HCL encapsulated in liposomes formulated with surface-bound methoxypolyethylene glycol
Study NCT03821454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
Study NCT03821454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match mirabegron
Description: Oral tablet
Study NCT02844933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral solution
Study NCT02844933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral solution
Study NCT01972841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match mirabegron
Description: Oral tablet
Study NCT03871751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe and Sound Protocol
Description: The auditory intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
Study NCT00684411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Study NCT00080756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic estradiol
Description: 0.35mg/100ul per day as a nasal spray
Study NCT00080756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic estradiol
Description: 0.35mg/100ul per day as a nasal spray
Study NCT00080756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deslorelin
Description: 1mg/100ul per day as a nasal spray
Study NCT00080756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deslorelin
Description: 1mg/100ul per day as a nasal spray
Study NCT00080756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic testosterone
Description: 0.275mg/100ul per day as a nasal spray
Study NCT00080756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic testosterone
Description: 0.275mg/100ul per day as a nasal spray
Study NCT00080756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo risk reduction mastectomy
Study NCT00080756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active surveillance
Description: Undergo continued surveillance
Study NCT00080756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00080756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00080756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00080756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03278613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ES-130
Description: The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device.
Study NCT03278613 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ES-130
Description: The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device.
Study NCT04607564 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ntombi Vimbela! intervention
Description: Ntombi Vimbela! constitutes a series of ten workshops running for a total 35 hours. The intervention is designed to raise awareness about sexual rights, violence against women and girls and its drivers; sensitise about gender inequality and build more gender equitable beliefs; sensitise about sexual assault; equip participants with skills to assess and act in situations where there is a high risk of sexual assault; build resilience and skills to withstand social and material pressures in college or university ; enable utilisation of health, psycho-social services and access to justice for survivors; enhance communication skills and building healthy sexual relationships; promote mental health and coping and build empathy towards survivors.
Study NCT02926157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Style and Sleep Intervention
Study NCT03197038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partially supervised home-based walking exercise
Description: Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.
Study NCT03197038 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
Study NCT02414243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Amino Acid formula
Description: Ordesa's Amino-Acid based Infant Formula
Study NCT02414243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Amino Acid Formula
Description: Commercially available Amino Acid Formula
Study NCT01413126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Whole peanuts without skins, Peanut butter, or no peanuts (control)
Description: In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
Study NCT01413126 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole peanuts without skins, Peanut butter, or no peanuts (control)
Description: In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
Study NCT03433196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 and Atorvastatin
Description: HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily
Study NCT03433196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
Study NCT00789841 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Tracking System (MTS) and radio-opaque markers
Description: MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
Study NCT02281435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device
Description: PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21)
Description: 4h exposure to heat (WBGT of 21°C), no solvent
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25)
Description: 4h exposure to heat (WBGT of 25°C), no solvent
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (30)
Description: 4h exposure to heat (WBGT of 30°C), no solvent
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Stress (21) +TOL
Description: 4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25) + TOL
Description: 4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21) + TOL
Description: 4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21) + ACE
Description: 4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25) + ACE
Description: 4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
Study NCT01103271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-label Placebo
Description: Participants take open-label placebo pills - two twice daily for four weeks.
Study NCT01103271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Open-label Placebo
Description: Participants take open-label placebo pills - two twice daily for four weeks.
Study NCT03126188 — intervention group
Intervention type: DRUG
Intervention: Sertraline
Description: Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
Study NCT03126188 — intervention group
Intervention type: DRUG
Intervention: Dosulepin
Description: Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (30) + ACE
Description: 4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21) + DCM
Description: 4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25) + DCM
Description: 4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (30) + DCM
Description: 4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21) + TOL (dermal)
Description: 4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25) + TOL (dermal)
Description: 4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
Study NCT02659410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (30) + TOL (dermal)
Description: 4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
Study NCT01052194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, placebo b.i.d. for 12 weeks
Study NCT01052194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: tablets, 25mg b.i.d. for 12 weeks
Study NCT01052194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: tablet, 50 mg b.i.d. for 12 weeks
Study NCT01052194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: tablet, 100 mg b.i.d. for 12 weeks
Study NCT01052194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: tablet, 150 mg b.i.d. for 12 weeks
Study NCT01095380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training
Description: Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
Study NCT03220204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PP-based health behavior intervention
Description: The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.
Study NCT03220204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-based educational control condition
Description: The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.